Chiao-Yin Sun1, Cheng-Jui Lin2, Heng-Chih Pan3, Chin-Chan Lee4, Shang-Chieh Lu5, Yu-Ting Hsieh3, Shih-Yi Huang6, Hui-Yu Huang7. 1. Department of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan; Kidney Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan; School of Medicine, Chang Gung University, Taoyuan, Taiwan; Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan. Electronic address: fish3970@gmail.com. 2. Division of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan; Mackay Junior College of Medicine, Nursing and Management, Taipei, Taiwan. 3. Department of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan; Kidney Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan. 4. Department of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan; School of Medicine, Chang Gung University, Taoyuan, Taiwan. 5. Department of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan; Kidney Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan. 6. Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei, Taiwan. 7. Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei, Taiwan; Department of Food Science, Nutrition, and Nutraceutical Biotechnology, Shih-Chien University, Taipei, Taiwan.
Abstract
BACKGROUND & AIMS: Emerging evidence indicates that gut microbiota serves an important role in the development and progression of chronic kidney disease (CKD). Changes to the gut microbial flora can cause the generation of uremic toxins, which contribute to chronic kidney injury. The aim of the current study was to explore the clinical association between metabolites and CKD. METHODS: Between August 2013 and January 2015, a two-phase case-control study was conducted to analyze the clinical association between metabolites and CKD in a community health program. The first phase of the study was a prospective case-control survey designed for comparing the differences in the metabolome profile of patients with (n = 10) and without (n = 10) estimated glomerular filtration rate (eGFR) rapid decline (a yearly decline >20%). The second phase of the study was a cross-sectional case-control study, which checked and compared the metabolites, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKD patients (n = 140). RESULTS: In the first phase of the study, it was revealed that IPA levels of patients with rapid renal function decline were significantly reduced compared with the control patients (n = 10 for each group). The second phase furthered checked and compared the IPA, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKD patients (n = 140). The results showed that the average level of indoxyl sulfate (2738.2 vs. 541.0 ng/ml, P < 0.01) and p-cresol sulfate (1442.8 vs. 1394.6 ng/ml, P < 0.01) were significantly higher in the CKD patients, while the average level of IPA was significantly higher (49.8 vs. 34.7 ng/ml, P < 0.01) in the control patients. CONCLUSIONS: Our results suggest that IPA might be an important biomarker and renal protector against the development of CKD.
BACKGROUND & AIMS: Emerging evidence indicates that gut microbiota serves an important role in the development and progression of chronic kidney disease (CKD). Changes to the gut microbial flora can cause the generation of uremic toxins, which contribute to chronic kidney injury. The aim of the current study was to explore the clinical association between metabolites and CKD. METHODS: Between August 2013 and January 2015, a two-phase case-control study was conducted to analyze the clinical association between metabolites and CKD in a community health program. The first phase of the study was a prospective case-control survey designed for comparing the differences in the metabolome profile of patients with (n = 10) and without (n = 10) estimated glomerular filtration rate (eGFR) rapid decline (a yearly decline >20%). The second phase of the study was a cross-sectional case-control study, which checked and compared the metabolites, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKDpatients (n = 140). RESULTS: In the first phase of the study, it was revealed that IPA levels of patients with rapid renal function decline were significantly reduced compared with the control patients (n = 10 for each group). The second phase furthered checked and compared the IPA, indoxyl sulfate and p-cresol sulfate levels between healthy subjects (n = 144) and CKDpatients (n = 140). The results showed that the average level of indoxyl sulfate (2738.2 vs. 541.0 ng/ml, P < 0.01) and p-cresol sulfate (1442.8 vs. 1394.6 ng/ml, P < 0.01) were significantly higher in the CKDpatients, while the average level of IPA was significantly higher (49.8 vs. 34.7 ng/ml, P < 0.01) in the control patients. CONCLUSIONS: Our results suggest that IPA might be an important biomarker and renal protector against the development of CKD.
Authors: Dara L Horn; Lisa F Bettcher; Sandi L Navarro; Vadim Pascua; Fausto Carnevale Neto; Joseph Cuschieri; Daniel Raftery; Grant E O'Keefe Journal: J Trauma Acute Care Surg Date: 2021-01-01 Impact factor: 3.313
Authors: Justin M Conley; Christy S Lambright; Nicola Evans; Elizabeth Medlock-Kakaley; Donna Hill; James McCord; Mark J Strynar; Leah C Wehmas; Susan Hester; Denise K MacMillan; L Earl Gray Journal: Environ Int Date: 2021-12-22 Impact factor: 9.621
Authors: Yuko Yamaguchi; Marta Zampino; Ruin Moaddel; Teresa K Chen; Qu Tian; Luigi Ferrucci; Richard D Semba Journal: Metabolomics Date: 2021-01-11 Impact factor: 4.747
Authors: Maren Gesper; Alena B H Nonnast; Nina Kumowski; Robert Stoehr; Katharina Schuett; Nikolaus Marx; Ben A Kappel Journal: Front Med (Lausanne) Date: 2021-03-22